Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 11/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 11/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 11/20 | 1.00 |
| ▸ | TNF | P01375 | 10/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120500 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6692793 | 0.94 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6098580 | 0.93 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL21215174 | 0.92 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6691297 | 0.92 | TNF (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6690004 | 0.92 | TNF (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL3121844 | 0.92 | TNF (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6098458 | 0.91 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6554664 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL9977590 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091356-B2 | Substituted alkanohydroxamic acids and method of reducing TNFα levels | CELGENE CORPORATION | 2006-08-15 | — | — | US | disclosed |
| US-20040006096-A1 | Substituted alkanohydroxamic acids and method of reducing TNFalpha levels | CELGENE CORPORATION | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006096-A1 | Substituted alkanohydroxamic acids and method of reducing TNFalpha levels | TNF, TNFRSF1A, LTA | PDE4A 10/4885PDE4B 54/4885PDE4C 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.